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Multiorgan failure is a frequent complication in critically 
ill patients, especially those suﬀ   ering from systemic 
inﬂ  ammatory syndromes [1,2]. Th   e functional changes in 
the aﬀ  ected patients are known to aﬀ  ect primarily the 
lungs, the cardiovascular system as well as the kidneys. 
While our therapeutic eﬀ  orts have therefore often been 
focused on these organ systems, it seems advisable to 
also include the gastrointestinal tract in the therapeutic 
management of critically ill patients [1]. Alterations in 
gastrointestinal motility are frequently found in such 
patients, leading to disturbances in nutrient absorption, 
induction of nausea and an increased risk of aspiration 
[1]. Furthermore, the gut has long been established as an 
important immune barrier, providing a safeguard against 
infectious complications [3]. For these reasons, tight 
clinical monitoring of gastrointestinal motility is central 
in the clinical management of critically ill patients, and 
the advantages of early enteral nutrition versus parenteral 
nutrient supplementation have been highlighted in 
numerous previous trials [3].
In the current issue of Critical Care, Dean and 
colleagues present a concise review that summarises the 
most important endocrine hormones secreted from the 
gut and discusses their functional alterations in critically 
ill patients [1]. Amongst those factors, the most promi-
nent is certainly the incretin hormone glucagon-like 
peptide (GLP)-1, a 29-amino-acid peptide secreted from 
intestinal L cells in response to nutrient ingestion [4]. In 
healthy individuals, this hormone is partly respon  sible 
for the augmentation of insulin responses to glucose and 
meal ingestion [5]. In addition, GLP-1 might play a role 
in the so-called ileal brake mechanism; that is, the 
deceleration of gastric emptying and acid secretion 
induced by the presence of nutrients in the ileum [6]. 
Th  ere is also good evidence for a role of GLP-1 in the 
cardiovascular system as well as in the central nervous 
control of appetite and food intake [4,7].
Owing to its potent glucose-lowering properties, two 
diﬀ   erent types of GLP-1-based therapies have now 
become available for the treatment of type 2 diabetes. 
Th   e GLP-1 analogues are injectable agonists at the GLP-1 
receptor with a prolonged biological half life, whereas the 
DPP-4 inhibitors prevent the proteolytic degradation of 
GLP-1, thereby raising its endogenous plasma concen-
trations [8]. Because the secretion of GLP-1 is stimulated 
by the absorption of nutrients from the gut, reductions in 
GLP-1 plasma concentrations are often caused by altera-
tions in gut motility and absorption [9]. Disturbances in 
GLP-1 plasma levels are therefore likely to occur in 
critically ill patients, which are prone to developing 
abnormal gastrointestinal motility. In particular, the 
release of incretin hormones is no longer stimulated in 
patients receiving total parenteral nutrition [10].
What are the potential consequences arising from 
impaired incretin hormone release in critically ill 
patients? Most obviously, the stimulation of insulin 
secretion would be diminished, whereas glucagon levels 
might increase. Also, the improvements in cardiac 
function observed during exogenous GLP-1 adminis  tra-
tion [11] might suggest deteriorations in cardiac 
functions in patients with low GLP-1 levels, although a 
role of endogenous GLP-1 in the cardiovascular system 
has not yet been fully established. On the other hand, 
reductions in GLP-1 plasma levels might also slightly 
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appears to be rather desirable in critically ill patients.
In light of the potential reductions in GLP-1 concen-
trations in critically ill patients, and because of the potent 
glucose-lowering eﬀ   ects of GLP-1 in diabetic patients 
with no risk of inducing hypoglycaemia [12], the eﬀ  ects 
of acute intravenous infusions of GLP-1 have been 
examined in initial proof-of-concept studies in critically 
ill patients after abdominal surgery [13], after cardiac 
surgery [14], during parenteral nutrition [10] as well as 
during enteral feeding [15]. Collectively, these studies 
have suggested a beneﬁ  cial role for GLP-1 treatment in 
critically ill patients.
When considering the exogenous administration of 
GLP-1 in such patients, however, it is still important to 
bear in mind that the gut also produces at least 30 to 50 
other peptide hormones [16], the physiological functions 
of which are still not fully elucidated. While the exoge-
nous administration of some of these hormones (for 
example, ghrelin, GLP-1, GLP-2) may provide certain 
beneﬁ  ts in terms of glucose homoeostasis, gastric empty-
ing or intestinal epithelial regeneration, mimicking the 
physiological responses of all major gastrointestinal 
hormones in critically ill patients is certainly far from 
realistic. From a pragmatic point of view, the easiest way 
to normalise the secretion of gastrointestinal hormones 
in such patients is to provide enteral nutrition as early as 
possible.
Overall, the review article by Dean and colleagues 
provides a state-of-the-art overview of our knowledge 
about the changes in gastrointestinal hormone secretion 
and action in critically ill patients [1]. At the same time, 
the complexity of the gut’s endocrine network and the 
multiple biological functions aﬀ  ected by gastrointestinal 
hormones clearly emphasise the need for further studies 
in this area in order to gain a better understanding of the 
biological functions of these hormones and their 
potential alterations in critically ill patients. Such future 
studies could then pave the way towards an implemen-
tation of gut hormone preparations in the acute manage-
ment of critical illnesses.
Ultimately, the endocrine failure of the gastrointestinal 
tract may be considered alongside other endocrine 
insuﬃ   ciencies in such patients, such as sympathoadrenal 
insuﬃ   ciency [17]. Along these lines, future therapeutic 
strategies may then also include the substitution of 
gastrointestinal hormones in critically ill patients, similar 
to the substitution of corticosteroids in septic patients.
Abbreviations
GI, gastrointestinal; GLP, glucagon-like peptide.
Competing interests
JJM has received speaker and advisory board honoraria from Novo Nordisk, Ely 
Lilly, MSD, Novartis, Astra Zeneca, and Sanofi  -Aventis.
Published: 22 September 2010
References
1.  Deane A, Chapman MJ, Fraser RJL, Horowitz M: Bench-to-bedside review: 
The gut as an endocrine organ in the critically ill. Crit Care 2010, 14:228.
2.  Opal SM, LaRosa SP: Year in review 2008: critical care – sepsis. Crit Care 2009, 
13:224.
3.  Kang W, Kudsk KA: Is there evidence that the gut contributes to mucosal 
immunity in humans? J Parenter Enteral Nutr 2007, 31:246-258.
4.  Meier JJ, Nauck MA: Glucagon-like peptide 1(GLP-1) in biology and 
pathology. Diabetes Metab Res Rev 2005, 21:91-117.
5.  Nauck MA, Heimesaat MM, Ørskov C, Holst JJ, Ebert R, Creutzfeldt W: 
Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not 
of synthetic human gastric inhibitory polypeptide in patients with type-2 
diabetes mellitus. J Clin Invest 1993, 91:301-307.
6. Nauck  MA:  Is glucagon-like peptide 1 an incretin hormone? Diabetologia 
1999, 42:373-379.
7.  Meier JJ, Gallwitz B, Schmidt WE, Nauck MA: Glucagon-like peptide 1 as a 
regulator of food intake and body weight: therapeutic perspectives. Eur J 
Pharmacol 2002, 440:269-279.
8.  Nauck MA, Meier JJ: Glucagon-like peptide 1 (GLP-1) and its derivatives in 
the treatment of diabetes. Regul Pept 2005, 124(Suppl):135-148.
9.  Chaikomin R, Doran S, Jones KL, Feinle-Bisset C, O’Donovan D, Rayner CK, 
Horowitz M: Initially more rapid small intestinal glucose delivery increases 
plasma insulin, GIP, and GLP-1 but does not improve overall glycemia in 
healthy subjects. Am J Physiol Endocrinol Metab 2005, 289:E504-E507.
10.  Nauck MA, Walberg J, Vethacke A, El-Ouaghlidi A, Senkal M, Holst JJ, Gallwitz 
B, Schmidt WE, Schmiegel W: Blood glucose control in healthy subject and 
patients receiving intravenous glucose infusion or total parenteral 
nutrition using glucagon-like peptide 1. Regul Pept 2004, 118:89-97.
11.  Nikolaidis LA, Mankad S, Sokos GG, Miske G, Shah A, Elahi D, Shannon RP: 
Eff  ects of glucagon-like peptide-1 in patients with acute myocardial 
infarction and left ventricular dysfunction after successful reperfusion. 
Circulation 2004, 109:962-965.
12.  Nauck MA, Kleine N, Ørskov C, Holst JJ, Willms B, Creutzfeldt W: 
Normalization of fasting hyperglycaemia by exogenous glucagon-like 
peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic 
patients. Diabetologia 1993, 36:741-744.
13.  Meier JJ, Weyhe D, Michaely M, Senkal M, Zumtobel V, Nauck MA, Holst JJ, 
Schmidt WE, Gallwitz B: Intravenous glucagon-like peptide 1 normalizes 
blood glucose after major surgery in patients with type 2 diabetes. Crit 
Care Med 2004, 32:848-851.
14.  Mussig K, Oncu A, Lindauer P, Heininger A, Aebert H, Unertl K, Ziemer G, 
Haring HU, Holst JJ, Gallwitz B: Eff  ects of intravenous glucagon-like 
peptide-1 on glucose control and hemodynamics after coronary artery 
bypass surgery in patients with type 2 diabetes. Am J Cardiol 2008, 
102:646-647.
15.  Deane AM, Chapman MJ, Fraser RJ, Burgstad CM, Besanko LK, Horowitz M: 
The eff  ect of exogenous glucagon-like peptide-1 on the glycaemic 
response to small intestinal nutrient in the critically ill: a randomised 
double-blind placebo-controlled cross over study. Crit Care 2009, 13:R67.
16. Schmidt  WE:  The intestine, an endocrine organ. Digestion 1997, 
58(Suppl 1):56-58.
17.  Mesotten D, Vanhorebeek I, Van den Berghe G: The altered adrenal axis and 
treatment with glucocorticoids during critical illness. Nat Clin Pract 
Endocrinol Metab 2008, 4:496-505.
doi:10.1186/cc9079
Cite this article as: Meier JJ: Waking up the gut in critically ill patients. 
Critical Care 2010, 14:183.
Meier Critical Care 2010, 14:183 
http://ccforum.com/content/14/5/183
Page 2 of 2